{"id":414810,"date":"2021-01-14T08:03:39","date_gmt":"2021-01-14T13:03:39","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=414810"},"modified":"2021-01-14T08:03:39","modified_gmt":"2021-01-14T13:03:39","slug":"eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle\/","title":{"rendered":"Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI\u00ae SPRINKLE"},"content":{"rendered":"<div class=\"mw_release\">\n<p>DEER PARK, Ill., Jan.  14, 2021  (GLOBE NEWSWIRE) &#8212; Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it has acquired Canadian rights to ALKINDI\u00ae SPRINKLE from Diurnal Group plc (LSE AIM: DNL). Eton Pharmaceuticals currently commercializes ALKINDI\u00ae SPRINKLE in the United States as a replacement therapy for Adrenocortical Insufficiency (AI) in children under 17 years of age.<\/p>\n<p>\u201cSince launching ALKINDI\u00ae SPRINKLE in the United States, we have been overwhelmed by the strong interest we have received from endocrinologists and caregivers in Canada,\u201d said Sean Brynjelsen, CEO of Eton Pharmaceuticals. \u201cWe are pleased to be expanding our partnership with Diurnal to include the Canadian market. This exciting acquisition will allow us to leverage the early success we have experienced with ALKINDI\u00ae SPRINKLE in the United States market and will further advance us towards our goal of becoming an industry leading orphan drug company.\u201d<\/p>\n<p>\u201dWe continue to be impressed by Eton\u2019s enthusiasm and vision for ALKINDI\u00ae SPRINKLE,\u201d said Martin Whitaker, CEO of Diurnal Group plc. \u201cWe are pleased to extend our collaboration with Eton to potentially bring the product to pediatric patients in Canada suffering with adrenal insufficiency, where there is a significant unmet patient need.\u201d<\/p>\n<p>\n        <strong>About ALKINDI SPRINKLE<\/strong><br \/>\n        <br \/>ALKINDI\u00ae SPRINKLE is an immediate-release oral hydrocortisone granule preparation that has been specifically designed to meet the dosing needs of pediatric patients with adrenocortical insufficiency. ALKINDI\u00ae SPRINKLE is manufactured using commercially proven technology in four strengths: 0.5 mg, 1 mg, 2 mg and 5 mg, to give greater dosing flexibility to clinicians. Taste-masking excipients that are acceptable for pediatric use eliminate the bitter taste of hydrocortisone. ALKINDI\u00ae SPRINKLE has a shelf -life of three years at ambient temperature and does not require refrigeration. Additional information for U.S. patients and healthcare professionals is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=W8r65P-__UMR-jAXw2Cqh3c7jl_HK0ktHHeD8-2LUFrQd9yKb1iakpI_ijeAunSmnlol2GfxZuX7SIvxwC3py28oW1ELhxNg789sgsQQ1fE=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.alkindisprinkle.com<\/a>.<\/p>\n<p><strong>About Eton Pharmaceuticals<\/strong><br \/>Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases. The company currently owns or receives royalties from three FDA-approved products, including ALKINDI\u00ae SPRINKLE, Biorphen\u00ae, and Alaway Preservative Free\u00ae, and has six additional products that have been submitted to the FDA.<\/p>\n<p><strong>Forward-Looking Statements<\/strong><br \/>Statements contained in this press release regarding matters that are not historical facts are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton\u2019s business strategy, Eton\u2019s plans to develop and commercialize its product candidates, the safety and efficacy of Eton\u2019s product candidates, Eton\u2019s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton\u2019s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;will,&#8221; &#8220;goal,&#8221; &#8220;potential&#8221; and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton\u2019s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton\u2019s development programs and financial position are described in additional detail in Eton\u2019s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.<\/p>\n<p><strong>Company Contact:<\/strong><br \/>David Krempa<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9UIGQZhGmvW6SWtOKPSPQHto--hKjtVIqjDmHCW1dy5brRKRwHsCZYirPsG5n3ceBpcIWaqaB9RAymj8dvp2Z4SkAhSoEczuOVyMmOyvAoI=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">dkrempa@etonpharma.com<\/a><br \/>612-387-3740<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNTYzMSMzOTE4MjAzIzIxMjI5ODQ=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/c945b6de-66f7-4867-812a-5a0ace859637\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>DEER PARK, Ill., Jan. 14, 2021 (GLOBE NEWSWIRE) &#8212; Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it has acquired Canadian rights to ALKINDI\u00ae SPRINKLE from Diurnal Group plc (LSE AIM: DNL). Eton Pharmaceuticals currently commercializes ALKINDI\u00ae SPRINKLE in the United States as a replacement therapy for Adrenocortical Insufficiency (AI) in children under 17 years of age. \u201cSince launching ALKINDI\u00ae SPRINKLE in the United States, we have been overwhelmed by the strong interest we have received from endocrinologists and caregivers in Canada,\u201d said Sean Brynjelsen, CEO of Eton Pharmaceuticals. \u201cWe are pleased to be expanding our partnership with Diurnal to include the Canadian market. This &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI\u00ae SPRINKLE&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-414810","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI\u00ae SPRINKLE - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI\u00ae SPRINKLE - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DEER PARK, Ill., Jan. 14, 2021 (GLOBE NEWSWIRE) &#8212; Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it has acquired Canadian rights to ALKINDI\u00ae SPRINKLE from Diurnal Group plc (LSE AIM: DNL). Eton Pharmaceuticals currently commercializes ALKINDI\u00ae SPRINKLE in the United States as a replacement therapy for Adrenocortical Insufficiency (AI) in children under 17 years of age. \u201cSince launching ALKINDI\u00ae SPRINKLE in the United States, we have been overwhelmed by the strong interest we have received from endocrinologists and caregivers in Canada,\u201d said Sean Brynjelsen, CEO of Eton Pharmaceuticals. \u201cWe are pleased to be expanding our partnership with Diurnal to include the Canadian market. This &hellip; Continue reading &quot;Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI\u00ae SPRINKLE&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-14T13:03:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNTYzMSMzOTE4MjAzIzIxMjI5ODQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI\u00ae SPRINKLE\",\"datePublished\":\"2021-01-14T13:03:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle\\\/\"},\"wordCount\":682,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNTYzMSMzOTE4MjAzIzIxMjI5ODQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle\\\/\",\"name\":\"Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI\u00ae SPRINKLE - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNTYzMSMzOTE4MjAzIzIxMjI5ODQ=\",\"datePublished\":\"2021-01-14T13:03:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNTYzMSMzOTE4MjAzIzIxMjI5ODQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNTYzMSMzOTE4MjAzIzIxMjI5ODQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI\u00ae SPRINKLE\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI\u00ae SPRINKLE - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle\/","og_locale":"en_US","og_type":"article","og_title":"Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI\u00ae SPRINKLE - Market Newsdesk","og_description":"DEER PARK, Ill., Jan. 14, 2021 (GLOBE NEWSWIRE) &#8212; Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it has acquired Canadian rights to ALKINDI\u00ae SPRINKLE from Diurnal Group plc (LSE AIM: DNL). Eton Pharmaceuticals currently commercializes ALKINDI\u00ae SPRINKLE in the United States as a replacement therapy for Adrenocortical Insufficiency (AI) in children under 17 years of age. \u201cSince launching ALKINDI\u00ae SPRINKLE in the United States, we have been overwhelmed by the strong interest we have received from endocrinologists and caregivers in Canada,\u201d said Sean Brynjelsen, CEO of Eton Pharmaceuticals. \u201cWe are pleased to be expanding our partnership with Diurnal to include the Canadian market. This &hellip; Continue reading \"Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI\u00ae SPRINKLE\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-14T13:03:39+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNTYzMSMzOTE4MjAzIzIxMjI5ODQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI\u00ae SPRINKLE","datePublished":"2021-01-14T13:03:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle\/"},"wordCount":682,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNTYzMSMzOTE4MjAzIzIxMjI5ODQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle\/","name":"Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI\u00ae SPRINKLE - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNTYzMSMzOTE4MjAzIzIxMjI5ODQ=","datePublished":"2021-01-14T13:03:39+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNTYzMSMzOTE4MjAzIzIxMjI5ODQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNTYzMSMzOTE4MjAzIzIxMjI5ODQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eton-pharmaceuticals-announces-acquisition-of-canadian-rights-for-alkindi-sprinkle\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI\u00ae SPRINKLE"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/414810","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=414810"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/414810\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=414810"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=414810"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=414810"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}